Business Wire

DEKA Laser and New York’s Romeo & Juliette: A Global Partnership for Advanced Epilation on Fifth Avenue

4.12.2024 13:00:00 CET | Business Wire | Press release

Share

DEKA Laser, global leader in medical laser technologies, proudly announces its new and prestigious partnership with Romeo & Juliette Hair Removal, the renowned center specialized in permanent hair removal located on world-famous Fifth Avenue in New York City. Thanks to this exclusive collaboration, Romeo & Juliette will become another global reference center for DEKA training on laser hair removal, with particular attention to the Again PRO Series line of equipment, and will host the innovative DEKA Epil Academy, an academy dedicated to the training and sharing of advanced hair removal treatment protocols.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204652458/en/

Located on one of the most elegant and most renowned avenues in the world, Romeo & Juliette Hair Removal is considered true excellence in the aesthetic and medical realm, and is frequented by celebrities, top models and prominent sports personalities. This new international training center will become the reference point for physicians and specialists from all over the world who wish to train on the most innovative and effective laser hair removal protocols, in particular for the treatment of all phototypes.

“The collaboration with Romeo & Juliette represents a significant achievement for DEKA”, says Paolo Salvadeo, DEKA Laser’s CEO. “This partnership allows us to take our quality and innovation standards to one of the most iconic and prestigious locations in the world, making the training experience unique in its type. I am proud to be able to give life to this project, which will contribute to the growth and diffusion of the Again PRO technology and our advanced hair removal protocols.

Also Chris Karavolas, Director of the Romeo & Juliette Center, expresses his enthusiasm for this new phase: “We are thrilled to cooperate with DEKA, a subsidiary of the El.En. Group, an absolute reference company in the world of laser technology. This synergy will allow us to offer cutting-edge treatments to our clients, constantly optimizing the protocols for every skin type. For us working side by side with DEKA and El.En. Group represents a unique growth and development opportunity”.

Chris Karavolas, with over twenty years of experience in the hair removal field, will work closely with the DEKA team to perfect the treatment protocols for every skin type, contributing to positioning Romeo & Juliette and DEKA Laser as global leaders in the sector.

The DEKA Epil Academy will position itself as a center of excellence in the hair removal training, attracting professionals the world over toward the famous Fifth Avenue, a meeting place of innovation, beauty and technology.

https://dekalaser.com/products/again-pro/
https://www.romeojuliettelaserhairremoval.com/

Information on DEKA

DEKA is a subsidiary of the EL.EN. multinational Group which has been the leader in the laser work for 40 years.

This Italian company, headquartered in Florence, has its roots in a culture whose dominant characteristic is excellence of thought. Thanks to its priceless cultural heritage and its unique historical background, DEKA enshrines a promise of universal value in its vision: Transforming each scientific discovery into a solid benefit for physicians and patients and translate each technological innovation into ongoing improvement in its product and services range to ameliorate the quality of people’s lives.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241204652458/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release

- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release

Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built

DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release

DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict

Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release

Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye